Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
In the last 90 days, Passage BIO, Inc. insiders filed 1 open-market purchase and 0 sales; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $206.1K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −5 vs. previous quarter
- 29
- 13F valueReported value at the end of Q2 2026
- $6.82M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding PASG, Q2 2026
No superinvestor reported holding PASG at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Passage BIO, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 (view filing)4:30 PM ET | Jun 25 | 4 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +50.1K | $4.12 | +$206.1K | +8.0%673.8K after | |
| Jan 12, 2026 (view filing) | Jan 8 | 4 days | Borthwick KathleenCFO | SSale | −2.06K | $18.44 | −$38.0K | −27.6%5.40K after | |
| Jan 12, 2026 (view filing) | Jan 8 | 4 days | Chou WilliamPRESIDENT AND CEO | SSale | −4.08K | $18.44 | −$75.2K | −38.5%6.52K after | |
| Sep 15, 2025 (view filing)8:05 PM ET | Sep 11 | 4 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share (Common Stock) | +325 | $6.96 | +$2.26K | +0.1%592.0K after | |
| Sep 15, 2025 (view filing)8:05 PM ET | Sep 12-15 | 3 days | Nichols Weston and 1 other10% Owner | PPurchase | +31.7K | $6.99 | +$221.5K | +5.4%623.7K after | 2 lots |
| Jul 24, 2025 (view filing)6:12 PM ET | Jul 22 | 2 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +13.1K | $5.44 | +$71.3K | +2.8%476.0K after | |
| Jul 24, 2025 (view filing)6:12 PM ET | Jul 23-24 | 1 day | Nichols Weston and 1 other10% Owner | PPurchase | +115.7K | $5.72 | +$662.5K | +24.3%591.7K after | 2 lots |
| Jun 26, 2025 (view filing)5:10 PM ET | Jun 24-26 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −583.7K | $0.3379 | −$197.2K | −8.8%6.07M after | 3 lots |
| Apr 24, 2025 (view filing)5:38 PM ET | Apr 22-24 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −235.6K | $0.3342 | −$78.7K | −3.4%6.65M after | 3 lots |
| Apr 17, 2025 (view filing)6:10 PM ET | Apr 15-17 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −149.1K | $0.3335 | −$49.7K | −2.1%6.89M after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Passage BIO, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 673,759 | $3.29M | 0.38% | +50,055+8.0% | Added |
| Vanguard Capital Management LLC | 113,964 | $556.1K | 0.00% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 107,025 | $522.3K | 0.00% | +107,025 | New |
| Ikarian Capital, LLC | 99,517 | $485.6K | 0.08% | +31,393+46.1% | Added |
| Yiheng Capital Management, L.P. | 86,097 | $420.2K | 0.18% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 47,892 | $233.7K | 0.00% | −85,720−64.2% | Reduced |
| Erste Asset Management GmbH | 40,665 | $197.2K | 0.00% | −44,597−52.3% | Reduced |
| Geode Capital Management, LLC | 37,026 | $180.7K | 0.00% | −4,354−10.5% | Reduced |
| Verdad Advisers, LP | 30,728 | $150.0K | 0.14% | +8,600+38.9% | Added |
| Boothbay Fund Management, LLC | 28,439 | $138.8K | 0.00% | +9,568+50.7% | Added |